Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Background: In adolescents and young adults who have refractory cancers, bone marrow failure syndromes, or primary immunological deficiencies, hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy option. (Rotz et al., 2017). It has been observed that during the first year following hematopoietic stem cell transplantation (HSCT), up to 85 percent of pediatric patients experience a decline in their pulmonary function (PF).